Logo image
Back
DIPG-17. CD155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma
Journal article   Open access   Peer reviewed

DIPG-17. CD155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma

Theophilos Tzaridis, Tanja Eisemann, Augusto F Andrade, Jennifer L Hope, Megan M Romero, Oren J Becher, Nada Jabado, Linda M Bradley and Robert J Wechsler-Reya
Neuro-oncology (Charlottesville, Va.), v 24(Suppl 1), pp i21-i21
03 Jun 2022
DOI: https://doi.org/10.1093/neuonc/noac079.074
url
https://doi.org/10.1093/neuonc/noac079.074View
Published, Version of Record (VoR) Open

Abstract

Diffuse Midline Glioma/DIPG
There is an unmet need for more effective treatment strategies for diffuse intrinsic pontine glioma (DIPG), a devastating brain tumour arising in children and young adults. While immunotherapy is emerging as a powerful approach to treatment of other cancers, clinical trials with immune checkpoint inhibitors have failed to show a survival benefit for DIPG patients. In this study, we analysed the expression of immune checkpoint molecules on the surface of human and murine DIPG cells by flow cytometry and identified CD155 and B7-H3 as the most highly expressed checkpoint molecules, with minimal expression of PD-L1, PD-L2, Galectin-9, CEACAM-1, CD86, CD252 and CD137. These findings were confirmed in primary patient samples from pediatric brain tumours, including high-grade gliomas, medulloblastomas and ependymomas. To test whether CD155 inhibition increases susceptibility to CD8+ T cell killing in vitro , we cultured DIPG cells expressing ovalbumin (OVA) with CD8+ T cells from OT-I mice, which express T cell receptors specific for OVA. Addition of CD155 blocking antibodies to these cultures increased expression of T cell activation markers (CD25, CD44 and CD69) as well as T cell-mediated tumour killing, supporting the notion that CD155 can function as an immune checkpoint in DIPG. In addition to its effects on T cells, CD155 also exerted direct effects on tumour cells: treatment with anti-CD155 antibodies led to impaired cell viability, and shRNA-mediated knockdown of CD155 resulted in reduced cell proliferation in vitro . Strikingly, knockdown of CD155 also led to reduced growth of DIPG cells in vivo , and mice transplanted with the CD155-deficient cells had a clear survival benefit compared to mice transplanted with wild type cells. These studies demonstrate that CD155 functions as an immune checkpoint and as a regulator of tumor growth in DIPG, and suggest that targeting CD155 could be a valuable therapeutic strategy for this devastating disease.

Metrics

12 Record Views

Details

Logo image